New Albany, Ohio, U.S: Bill Anderson, Global CEO, Bayer, left, and Ohio Governor Mike Dewine shake hands on stage Friday, October 2, 2026 at an event where Bayer Pharmaceuticals said it will invest .2 billion in a new pharmaceutical manufacturing campus in the New Albany International Business Park. The new manufacturing plant is slated to bring hundreds of jobs to the region. Gov. Mike DeWine said the .2 billion plant would be Bayer s first pharmaceutical manufacturing and processing plant in North America. He said it also marked Ohio s largest international healthcare project, as well as the largest German investment in state history. Ã’One of the points that we made to Bayer was our proximity to seven major research uni - ZUMAd149 20261002_zap_d149_004
Choose your license
Rights Managed:
One-time editorial use in an online article, social media channels, internal presentation, website, newsletter, or blog.
One-time editorial use in a book, newspaper or magazine (excluding cover page), external presentation. Limited to 5,000 circulation. This includes the rights available in the Standard license.
Media Info
Credit: ZUMA Press Wire
Media ID:
Recording Date: Oct 2, 2026
Media Size: 6,000×4,002 Pixels
#2 October 2, 2026, New Albany, Ohio, U.S: Bill Anderson, Global CEO, Bayer, left, and Ohio Governor Mike Dewine shake hands on stage Friday, October 2, 2026 at an event where Bayer Pharmaceuticals said it will invest .2 billion in a new pharmaceutical manufacturing campus in the New Albany International Business Park. The new manufacturing plant is slated to bring hundreds of jobs to the region. Gov. Mike DeWine said the .2 billion plant would be Bayer s first pharmaceutical manufacturing and processing plant in North America. He said it also marked Ohio s largest international healthcare project, as well as the largest German investment in state history. Ã’One of the points that we made to Bayer was our proximity to seven major research uni - ZUMAd149 20261002_zap_d149_004
Release Info: Do I need a release?
Captions may have been translated or enriched by an AI system.
For more information about AI-assisted captions, see AI-assisted captions.
Need a custom license?
If your intended use isn't covered by the available options (such as non-editorial purposes or specific distribution needs), contact us. Our team will be happy to provide a tailored offer based on your requirements.
